Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) announced as Lead Clinical Program

January 15, 2025

Development plans of NY-500, an AI-Optimized PD-1 x VEGF Bifunctional Antibody, announced in multiple oncology indications

January 15, 2025

Advancement of Ph 1 clinical programs, RP-1664 and RP-3467, to be continued 

January 15, 2025

Investigator-initiated trial (IIT) initiated in China for KJ-C2219 for the treatment of R/R B-NHL

January 7, 2025

First Patient Dosed in Ph 1 Trial of HX044

January 7, 2025

NAVAL-1 Trial of Nana-val in R/R EBV+ lymphomas to be closed

December 31, 2024

First patient enrolled in Ph 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA in patients with unresectable or metastatic melanoma

December 26, 2024

First patient dosed in Ph 1 trial of IMC-P115C in patients with PRAME-expressing tumors

December 25, 2024

FHD-286 Clinical Development Program discontinued

December 25, 2024

KeyVibe and KEYFORM Clinical Programs of Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab to be discontinued

December 18, 2024

Inupadenant NSCLC program deprioritized after Ph 2 A2A-005 results announcement

December 18, 2024

Development of CT-0525 program to be discontinued

December 18, 2024

Reprioritized pipeline focus on LAVA-1266 and plan to discontinue development of LAVA-1207

December 18, 2024

Efficacy threshold not achieved in Ph 1 dose escalation trial for FHD-286 + decitabine to support continued development in patients with R/R AML 

December 18, 2024

First Patient dosed in Ph 1b Expansion Cohorts with ADRX-0706 Nectin-4 ADC

December 10, 2024

DSMB recommends continuation of Ph 3 study of Bria-IMT™ + an immune checkpoint inhibitor in metastatic breast cancer patients

December 10, 2024

Doses Selected for Ph 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Ph 1a Dose Escalation for JANX007 in mCRPC

December 10, 2024

First Patient Enrolled in Taiwan for Ph 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC Patients

December 10, 2024

First Patient Dosed in Ph 3 Clinical trial of HLX22/AC101 in 1L HER2-positive advanced gastric/GEJ cancer

December 10, 2024

Datopotamab Deruxtecan and Datopotamab Deruxtecan + Durvalumab Arms completed in the I-SPY2 Trial for Stage 2/3 Neoadjuvant Breast Cancer

December 10, 2024

Patient Enrollment Expanded for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM as UVA Cancer Center Doses First Patient

December 4, 2024

MDG1015 clinical trial in solid tumors to be paused

December 4, 2024

First patient dosed in Ph 3 trial HLX22-GC-301 of HLX22 in combination with trastuzumab and chemo in 1L HER2+ve advanced G/GEJ cancer patients

November 26, 2024

First Patient Dosed in Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

November 26, 2024

Enrollment of 68 patients completed in Ph 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule

November 26, 2024
Page1 Page2 Page3 Page4 Page5 Page6 … Page22

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.